Molecular Partners AG, a biopharmaceutical company in Switzerland, has filed Form F-1 Registration Statement on April 22, 2021 with the U.S. Securities and Exchange Commission to raise up to $100 million IPO. Pricing terms are yet to announce.
The company is a clinical-stage biopharmaceutical company applying our pioneering DARP in product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology.
The Zurich, Switzerland-based company was founded in 2004 and plans to list on the Nasdaq Global Market under the symbol “MOLN.” J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets are underwriters of the IPO.
The company engages Homburger AG as US Securities Counsel, and KPMG AG as Independent Auditor.
#ipo #Nasdaq #biopharmaceutibal #MolecularPartner #diseases
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
